Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals


Actinogen Medical (ASX:ACW) is developing a promising oral treatment for Alzheimer’s and depression and is accelerating clinical trials with new capital.

CEO Steven Gourlay, joins The Market Onlineto discuss the company’s development.

Join the discussion: See what HotCopper users are saying about Actinogen Medical Ltd and be part of the conversations that move the markets.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.